HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Cervical Cancer.
Measles cases continue to rise in US amid lagging vaccination rates – Pharmaceutical Technology
Share this article The CDC has identified 36 US states where less than 95% of children in kindergarten have been vaccinated against measles this year,